Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma

2009317 citationsJournal Articlebronze Open Access

Authors

Giorgio Perilongo · University of Padua

Rudolf Maibach · International Breast Cancer Study Group

Elisabeth Shafford · Children's Cancer and Leukaemia Group

Laurence Brugières · Institut Gustave Roussy

Penelope Brock · Great Ormond Street Hospital

Bruce Morland · Birmingham Children's Hospital

Beatriz de Camargo

Abstract

As compared with cisplatin plus doxorubicin, cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma. Doxorubicin can be safely omitted from the treatment of standard-risk hepatoblastoma. (ClinicalTrials.gov number, NCT00003912.)

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Lung Cancer Research Studies Testicular diseases and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 17, pp. 1662-1670

DOI: 10.1056/nejmoa0810613

Field-Weighted Citation Impact: 10.15